Strong Inhalation portfolio to drive growth…
Cipla is one of the largest producers of pMDIs (Metered Dose Inhalers) in the world with more than 65 different inhaled devices. Cipla derives 54% of its revenue from exports and 39% from domestic business.
Valuations:
We expect Cipla’s revenue and PAT to grow at a moderate CAGR of 13% and 14.5%, respectively over FY16-19E on account of key inhalation launches and scale up of US revenue from InvaGen acquisition. Hence, we recommend BUY rating on the stock with a TP of Rs633 at 22.5x FY19E earnings in-line with the peers.
Investments in equity shares, debentures, etc., are not obligations of, or guaranteed by Wealth India Financial Services Pvt. Ltd., and are subject to investment risks. Click here to read our full disclaimer.
Wealth Conversations – April 2024- Temporary suspension of subscriptions in ” Mirae Asset Global Electric & Autonomous Vehicles ETFs Fund of Fund & Mirae Asset Global X Artificial Intelligence & Technology ETF Fund of Fund
- Merger Announcement: Aditya Birla Sun Life CRISIL IBX AAA Mar 2024 Index Fund
Here is everything that you need to know about Arbitrage Funds- Temporary suspension of subscriptions in “DSP US Treasury Fund of Fund”
